Compounds
Psilocybin
Summary
Psilocybin is the prodrug active compound in psilocybin mushrooms, converted in the body to psilocin. Under investigation for treatment-resistant depression, PTSD, OCD, alcohol use…
Research notes
Context, reporting, and structured background for this dossier.
Psilocybin is the prodrug active compound in psilocybin mushrooms, converted in the body to psilocin. Under investigation for treatment-resistant depression, PTSD, OCD, alcohol use disorder, and other indications. Approved for therapeutic use in Australia in 2023. Remains Schedule I in the United States. Over 100 active clinical trials globally as of early 2026.
Related entities
Other dossiers that help connect this page to the wider reporting record.
- Treatment-Resistant Depression (TRD)
Treatment-resistant depression is generally defined as depression that has failed to respond to at least two adequate antidepressant trials. Affects roughly 30% of people with majo…
- Compass Pathways
Compass Pathways is one of the most advanced public-company psilocybin developers, with a large Phase 3 COMP360 program in treatment-resistant depression and an FDA-authorized PTSD IND path.
- Cybin, now Helus Pharma
Cybin, now Helus Pharma, is a biopharmaceutical company developing deuterated serotonergic compounds, with HLP003/CYB003 now positioned inside a Phase 3 depression program.
- FDA
The U.S. Food and Drug Administration is the gatekeeper for psychedelic drug development in the United States, from IND clearance through advisory committee review and any eventual approval or rejection.